Financials Alzamend Neuro, Inc.

Stocks

ALZN

US02262M6057

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2026-08-14 EDT			5-day change	1st Jan Change
1.550 ^USD	+6.16%		+13.14%	-14.84%

08-04	Alzamend Neuro Announces Initial Closing of Securities Purchase Agreement with Ault Lending	CI
07-22	Alzamend Neuro, Inc. Reports Earnings Results for the Full Year Ended April 30, 2026	CI

Projected Income Statement: Alzamend Neuro, Inc.

Fiscal Period: April	2022	2023	2024	2025	2026	2027
Net sales ¹	-	-	-	-	-	-
Change	-	-	-	-	-	-
EBITDA ¹	-7.907	-11.26	-8.931	-4.121	-7.949	-10.7
Change	-	-42.46%	20.72%	53.86%	-92.88%	-34.62%
EBIT ¹	-12.32	-14.87	-9.938	-4.497	-8.767	-10.8
Change	-	-20.71%	33.17%	54.75%	-94.96%	-23.19%
Interest Paid	-0.0465	-0.0077	-	-	-	-
Earnings before Tax (EBT) ¹	-12.36	-14.88	-9.948	-4.515	-8.772	-10.8
Change	-	-20.35%	33.14%	54.61%	-94.3%	-23.11%
Net income ¹	-12.36	-14.88	-9.948	-5.105	-8.772	-10.8
Change	-	-20.35%	33.14%	48.68%	-71.84%	-23.11%
Announcement Date	7/19/22	7/27/23	7/30/24	7/22/25	7/22/26	-

¹USD in Million

Estimates

Fiscal Period: April	2022 Q2	2022 Q3	2022 Q4	2023 Q1	2023 Q2	2023 Q3	2023 Q4	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2025 Q1	2025 Q2	2025 Q3	2025 Q4	2026 Q1	2026 Q2	2026 Q3	2026 Q4	2027 Q1	2027 Q2	2027 Q3	2027 Q4
Net sales ¹	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Change	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EBITDA ¹	-2.304	-1.426	-2.615	-	-2.385	-3.91	-2.808	-3.513	-2.571	-2.461	-0.7561	-0.8684	-1.264	-0.9434	-1.045	-2.63	-0.9389	-2.161	-2.219	-2.7	-2.7	-2.7	-2.7
Change	-	38.11%	-83.41%	-	-	-63.91%	28.17%	-25.1%	26.83%	4.28%	69.27%	-14.86%	-45.56%	25.37%	-10.76%	-151.64%	64.29%	-130.13%	-2.72%	-21.66%	0%	0%	0%
EBIT ¹	-3.584	-2.557	-3.873	-3.036	-3.106	-5.424	-3.305	-3.526	-2.902	-2.66	-0.8501	-0.9624	-1.358	-1.037	-1.139	-2.7	-0.9981	-2.198	-2.871	-2.7	-2.7	-2.7	-2.7
Change	-	28.67%	-51.48%	21.62%	-2.33%	-74.59%	39.06%	-6.68%	17.7%	8.33%	68.04%	-13.22%	-41.11%	23.61%	-9.79%	-137.08%	63.04%	-120.18%	-30.63%	5.95%	0%	0%	0%
Charge d'intérêts	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings before Tax (EBT) ¹	-3.6	-2.573	-3.869	-	-3.11	-5.426	-3.306	-3.528	-2.906	-2.662	-0.8515	-0.9744	-1.362	-1.039	-1.139	-2.703	-1.001	-2.199	-2.87	-2.7	-2.7	-2.7	-2.7
Change	-	28.53%	-50.39%	-	-	-74.46%	39.07%	-6.72%	17.62%	8.38%	68.02%	-14.43%	-39.73%	23.66%	-9.62%	-137.19%	62.97%	-119.73%	-30.51%	5.92%	0%	0%	0%
Net income ¹	-3.6	-2.573	-3.869	-3.037	-3.11	-5.426	-3.306	-3.528	-2.906	-2.662	-0.8515	-0.9744	-1.415	-1.039	-1.73	-2.703	-1.001	-2.199	-2.87	-2.7	-2.7	-2.7	-2.7
Change	-	28.53%	-50.39%	21.51%	-2.4%	-74.46%	39.07%	-6.72%	17.62%	8.38%	68.02%	-14.43%	-45.24%	26.55%	-66.41%	-56.25%	62.97%	-119.73%	-30.51%	5.92%	0%	0%	0%
Announcement Date	12/13/21	3/15/22	7/19/22	9/13/22	12/12/22	3/15/23	7/27/23	9/13/23	12/15/23	3/25/24	7/30/24	9/11/24	12/11/24	3/10/25	7/22/25	9/10/25	12/9/25	3/11/26	7/22/26	-	-	-	-

¹USD in Million

Estimates

Forecast Balance Sheet: Alzamend Neuro, Inc.

Fiscal Period: April	2022	2023	2024	2025	2026	2027
Net Debt	-	-	-	-	-	-
Change	-	-	-	-	-	-
Announcement Date	7/19/22	7/27/23	7/30/24	7/22/25	7/22/26	-

Estimates

Cash Flow Forecast: Alzamend Neuro, Inc.

Fiscal Period: April	2021	2022	2023	2024	2025	2026
CAPEX ¹	-	0.1065	-	0.1472	0.3	-
Change	-	-	-	-	103.74%	-
Free Cash Flow (FCF) ¹	-0.4688	-2.189	-4.333	-4.688	-5.186	-4.779
Change	-	-366.97%	-97.96%	-8.18%	-10.63%	7.85%
Announcement Date	7/29/21	7/19/22	7/27/23	7/30/24	7/22/25	7/22/26

¹USD in Million

Estimates

Forecast Financial Ratios: Alzamend Neuro, Inc.

Fiscal Period: April	2021	2022	2023	2024	2025	2026	2027
Profitability
EBITDA Margin (%)	-	-	-	-	-	-	-
EBIT Margin (%)	-	-	-	-	-	-	-
EBT Margin (%)	-	-	-	-	-	-	-
Net margin (%)	-	-	-	-	-	-	-
FCF margin (%)	-	-	-	-	-	-	-
FCF / Net Income (%)	-	54.36%	59.97%	-	-	-	-
Profitability
ROA	-130.96%	-88.35%	-90.98%	-189.73%	-107.38%	-163.99%	-
ROE	-356.06%	-160.92%	-181.47%	-4,408.31%	-657.17%	-373.18%	-
Financial Health
Leverage (Debt/EBITDA)	-	-	-	-	-	-	-
Debt / Free cash flow	-	-	-	-	-	-	-
Capital Intensity
CAPEX / Current Assets (%)	-	-	-	-	-	-	-
CAPEX / EBITDA (%)	-	-1.35%	-	-1.65%	-7.28%	-	-
CAPEX / FCF (%)	-	-1.58%	-	-	-	-	-
Items per share
Cash flow per share ¹	-	-	-	-	-	-	-
Change	-	-	-	-	-	-	-
Dividend per Share ¹	-	-	-	-	-	-	-
Change	-	-	-	-	-	-	-
Book Value Per Share ¹	-	188.7	-	-34.51	-	0.1723	-2.59
Change	-	-	-	-	-	-	-1,603.19%
EPS ¹	-	-189	-202.5	-132.3	-11.32	-2.63	-2.6
Change	-	-	-7.14%	34.67%	91.44%	76.77%	1.14%
Nbr of stocks (in thousands)	-	68.9	71.8	76.3	734	3,805	4,792
Announcement Date	-	7/19/22	7/27/23	7/30/24	7/22/25	7/22/26	-